UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 24, 2004



                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)


               Delaware                0-16375              94-3018487
               ---------               --------             ----------
(State or other jurisdiction of      (Commission          (I.R.S. Employer
 incorporation or organization)      File Number)        Identification No.)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))

<PAGE>


Section 8 - Other Events
------------------------

Item 8.01 Other Events.

     On November 24, 2004,  ThermoGenesis  Corp. (the "Company") provided update
on a press release on its Thrombin  Processing Device ("TPD") and DAC System for
the semi-automated separation of whole blood. The FDA determined that the TPD is
not substantially equivalent to devices marketed in interstate commerce prior to
May 28, 1976 or to any device which has been  reclassified into Class I or Class
II and  therefore,  the TPD has  been  classified  by  statute  into  Class  III
(Pre-Market  Approval  ("PMA")).  The FDA has  reviewed  the DAC  System  510(k)
submission  for the  semi-automated  separation  of whole blood and  freezing of
blood   components   and  requires   additional   information  to  complete  its
determination  of  substantial  equivalency  to devices  marketed in  interstate
commerce.  ThermoGenesis  has recently provided  additional  information for the
FDA's review.  Additional information can be found on the press release attached
as Exhibit 99.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

         Exhibit No.        Exhibit Description
         -----------        -------------------
             99             Press Release Updating  Regulatory  Clearance Status
                            for Autologous Thrombin Processing  Device (TPD(TM))
                            and the DAC(TM) System


<PAGE>


                                    SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                        THERMOGENESIS CORP.,
                                                        a Delaware Corporation


Dated:  November 29, 2004                               /s/ Renee M. Ruecker
                                                        ------------------------
                                                        Renee Ruecker,
                                                        Chief Financial Officer


<PAGE>


                                  EXHIBIT INDEX


         Exhibit No.        Description
         -----------        -----------
             99             Press  Release  dated  November  24,  2004    titled
                            "Thermogenesis  Updates  Regulatory Clearance Status
                            for Autologous Thrombin Processing  Device (TPD(TM))
                            and the DAC(TM) System "
[{"type": "8-K", "sequence": "1", "filename": "for112404.txt", "secsgml_size_bytes": 4515}]
{"company-data": {"conformed-name": "THERMOGENESIS CORP", "cik": "0000811212", "assigned-sic": "3821", "irs-number": "943018487", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "333-82900", "film-number": "041172763"}, "business-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742", "phone": "9168585100"}, "mail-address": {"street1": "2711 CITRUS ROAD", "city": "RANCHO CORDOVA", "state": "CA", "zip": "95742"}, "former-company": {"former-conformed-name": "INSTA COOL INC OF NORTH AMERICA", "date-changed": "19920703"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 24, 2004

                               THERMOGENESIS CORP.
             (Exact name of registrant as specified in its charter)

               Delaware                0-16375              94-3018487
               ---------               --------             ----------
(State or other jurisdiction of      (Commission          (I.R.S. Employer
 incorporation or organization)      File Number)        Identification No.)

                                2711 Citrus Road
                        Rancho Cordova, California 95742
                        --------------------------------
    (Address and telephone number of principal executive offices) (Zip Code)

                                 (916) 858-5100
                                 --------------
              (Registrant's telephone number, including area code)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)
[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))
Section 8 - Other Events
------------------------

Item 8.01 Other Events.

     On November 24, 2004,  ThermoGenesis  Corp. (the "Company") provided update
on a press release on its Thrombin  Processing Device ("TPD") and DAC System for
the semi-automated separation of whole blood. The FDA determined that the TPD is
not substantially equivalent to devices marketed in interstate commerce prior to
May 28, 1976 or to any device which has been  reclassified into Class I or Class
II and  therefore,  the TPD has  been  classified  by  statute  into  Class  III
(Pre-Market  Approval  ("PMA")).  The FDA has  reviewed  the DAC  System  510(k)
submission  for the  semi-automated  separation  of whole blood and  freezing of
blood   components   and  requires   additional   information  to  complete  its
determination  of  substantial  equivalency  to devices  marketed in  interstate
commerce.  ThermoGenesis  has recently provided  additional  information for the
FDA's review.  Additional information can be found on the press release attached
as Exhibit 99.

Section 9 - Financial Statements and Exhibits
---------------------------------------------

Item 9.01 Financial Statements and Exhibits.

         Exhibit No.        Exhibit Description
         -----------        -------------------
             99             Press Release Updating  Regulatory  Clearance Status
                            for Autologous Thrombin Processing  Device (TPD(TM))
                            and the DAC(TM) System
SIGNATURE

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                                        THERMOGENESIS CORP.,
                                                        a Delaware Corporation

Dated:  November 29, 2004                               /s/ Renee M. Ruecker
                                                        ------------------------
                                                        Renee Ruecker,
                                                        Chief Financial Officer
EXHIBIT INDEX

         Exhibit No.        Description
         -----------        -----------
             99             Press  Release  dated  November  24,  2004    titled
                            "Thermogenesis  Updates  Regulatory Clearance Status
                            for Autologous Thrombin Processing  Device (TPD(TM))
                            and the DAC(TM) System "